Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Inclusion Criteria:

For the SAD study:

1. Healthy adults aged 18-45 years (inclusive) at the time of signing the informedconsent form;

2. Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg; body mass index (weight/square of height (kg/m2)) within the range of 18-28kg/m2 (inclusive);

3. Normal results or abnormal results but without clinical significance incomprehensive examinations, including general physical examination, vital signs,laboratory tests, 12-lead ECG, abdominal color Doppler ultrasound, and chest X-rayfrom the frontal and lateral position ;

For the MAD study:

1. Male or female participants aged 18-65 years (inclusive) at the time of signing theinformed consent form;

2. Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg;

3. Chronic plaque psoriasis for at least 6 months with or without psoriatic arthritis;

Exclusion Criteria:

For the SAD study:

1. Participants with immune-related diseases and medical history at screening;

2. Participants with a history of drug or other allergies who are considered by theinvestigator to be at high risk for participating in this study, or who may beallergic to the investigational medicinal product or any component of theinvestigational medicinal product as judged by the investigator;

3. History of drug abuse within the past 5 years or use of illicit drugs within 3months before the study; or positive for urine drug screening;

For the MAD study:

1. Guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-inducedpsoriasis, or other diseases that affect the treatment results;

2. Current use of illicit drugs or prior use of illicit drugs within the specific timeperiods;

3. Known history of recurrent or chronic infections, or prior history of chronic orrecurrent infections, including but not limited to: chronic renal infection, chronicchest infection (e.g., bronchiectasis), symptomatic urinary tract infection, andopen, draining, or infected skin wounds; history of serious infections (e.g.,sepsis, pneumonia, and pyelonephritis), or hospitalization or treatment withintravenous antibiotics for infections within 2 months before screening;